KR101771488B1 - Novel Bacillus coagulans NRR1207, fermented ginseng using the same and probiotic composition containing the same - Google Patents

Abstract

The present invention provides a novel Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) and fermented ginseng using the same. The Bacillus coagulans NRR1207 strain is excellent in converting ginsenosides of low-bioavailability ginseng into ginsenosides with good bioavailability.
Also provided is a probiotic prophylactic composition using the novel Bacillus coagulans NRR1207 strain of the present invention. The above-mentioned Bacillus coagulans NRR1207 is excellent in the function of decomposing the stubbyose and raffinose which are the indigestible components contained in the raw materials for feeds.
Therefore, it is expected that the novel Bacillus coagulans NRR1207 strain of the present invention can be used for the development of health functional foods, and for the development of probiotics for proteolytic degradation and protein degradation.

Description

A novel Bacillus coagulans NRR1207 strain, a fermented ginseng and a probiotic prophylactic composition using the same, {Novel Bacillus coagulans NRR1207, fermented ginseng using the same and probiotic composition containing same same}

The present invention provides a novel Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) and fermented ginseng using the same.

The present invention also provides a probiotic prophylactic composition comprising the Bacillus coagulans NRR1207 strain.

Ginseng (Panax ginseng) has been widely used as a drug or health food in the East, including the country for thousands of years past as a herbaceous perennial belonging to the genus Araliaceae senticosus (Aralaiaceae) ginseng. In addition, ginseng can be used in various forms such as ginseng and red ginseng. In particular, it is known that red ginseng processed by steaming steam ginseng contains various ginsenosides useful for the human body.

Saponin, which represents the main efficacy of ginseng, is composed of more than 30 kinds of ginsenosides. Ginsenosides are used to enhance immunity, antiinflammatory action, antiallergic action, anti-cancer effect, effect on erectile dysfunction, Cholesterol action, antithrombotic action, adult disease and aging.

Saponin of ginseng is a neutral glycoside in which glucose, arabinose, xylose, rhamnose and the like are bonded to a triterpenoid-based dammarane skeleton. When ginseng was extracted with water and alcohol, it was confirmed that Rb1, Rb2, Rc, Rg1 and the like were abundant in the ginsenoside of ginseng. However, these ginsenosides are not well absorbed in the body and are not suitable for use as a pharmaceutical composition.

The ginsenosides in the ginseng are converted into ginsenosides which are not present in the natural world through the process of processing them with red ginseng or black ginseng, so that the ginsenosides can be absorbed well in the body and can be suitably used for pharmaceutical compositions of various diseases.

That is, the glycosyl residues are separated from Rb1, Rb2, Rc, Rg1 and the like among the ginsenosides of ginseng to produce ginsenosides Rg2, Rg3, Rh2, Rh1 and the like at the processing step, Rg5, Rk1, Rg6, Rk3, F4 and Rh4 are known to be generated through the process.

In addition, the ginsenosides are hydrolyzed by the addition of an organic acid, and the sugar is removed and the side chain portion is cyclized to form Panaxatriol or Panaxadiol (Shibata S. et al. Shibata S. et al., 1974; Shibata S. et al., 1974).

On the other hand, when ginsenosides enter the body, ginsenosides such as Rb1, Rb2, Rc, and Rg1 are degraded by intestinal microorganisms and can be absorbed (Hasegawa H. et al., 1996). The ginsenosides are sequentially degraded by intestinal microorganisms and Rb1 is sequentially converted to Rd, Compound K and protopanaxadiol, but the presence or absence of microorganisms and the presence or absence of microorganisms (Akao T. et al., 1998). In addition, there is a significant difference in the degree of absorption due to the conversion of metabolites.

Therefore, in order to eliminate the difference between the efficacy and the absorption rate in the body by the conversion of the metabolite, the ginsenoside absorption rate of the body is increased through the conversion of the ginsenoside in the ginseng by the microorganism, There is a need for development of fermented ginseng which is strengthened en masse.

Feed refers to a material containing livestock, organic matter, and mineral nutrients that are required to sustain life, produce livestock, and grow, reproduce, and feed. Good feed conditions should be high in nutrient supply to livestock, harmless, non-toxic, high yield, easy to use, nutrients that are not easily altered, and high digestibility of nutrients.

Materials used in the production of feed include grains, barns, oil meals, industry by-products, feeds from animals, fruits and vegetables, Root and stems, farm by-products, soiling crops, silage, and so on. These materials, however, contain a number of indigestible components that animals can not digest.

For example, in the case of soybean meal, the soybean meal is a by-product obtained by pulverizing soybean and extracting the oil with hexane. As a by-product, the constituents include 55 to 56% of protein, 13 to 14% of soluble carbohydrate, 21 to 21% of insoluble carbohydrate 21 (22%), ash (4 ~ 6%) and local fat (1%) (Han, Kyu, 1998). In the case of carbohydrates, monosaccharides are rarely found in soybean meal. Oligosaccharides are composed of sucrose, maltose, raffinose, and stachyose in an amount of 8.1%, 0.6%, 1.1% and 4.9%, respectively. Polysaccharide is composed of 15.0% arabinan, 5.0% arabinogalactan, 3.5% hemicellulose, and 2.0% cellulose. Among these, stachyose and raffinose are composed of? -Galactosyl linkages and are incapable of digesting them in animals that do not have? -Galactosidase enzyme (Stale R. et al , 1999).

Therefore, in order to improve the quality of feed, technology development using microbial fermentation technology capable of helping decomposition of indigestible components contained in feed ingredients is actively promoted both domestically and externally.

Thus, the inventors of the present invention have found that, among many fermenting microorganisms, there is an activity of converting ginsenoside into ginsenoside which can increase the absorption rate of ginsenoside, and as a result of continuous research to identify microorganisms capable of decomposing the indigestible component, The present invention can be completed by securing a microorganism having both glucosidase enzyme activity and? -Galactosidase enzyme activity.

As a prior art, Korean Patent No. 1423100 discloses a method for producing fermented red ginseng which amplifies the content of ginsenosides Rg3 and Rb1, but a strain completely different from the strain used in the present invention was used. Korean Patent No. 1343434, Korean Registered Patent No. 1343410, and Korean Patent No. 1345226 disclose that a lactobacillus plantarum strain, a Enterococcus faecalis strain and a Fannibacillus subsp. And discloses a method for producing fermented ginseng using this strain. However, this method differs from the present invention in that fermented ginseng is manufactured using a strain completely different from the present invention.

Korean Patent Laid-Open Publication No. 2014-0061915 discloses a method for producing fermented soybean meal and fish meal using a novel microorganism, Bacillus coagulans KM-1, but a strain different from the present invention was used.

Korean Registered Patent No. 1423100, a method for producing fermented red ginseng which amplifies the content of ginsenoside Rg3 and Rb1, Korean Registered Patent No. 1343434, New Enterococcus faecalis CRNB-A3 (KCTC11930 BP) strain having ginseng extract efficacy and saponin conversion method using the same. Korean Registered Patent No. 1343410, Novel Lactobacillus plantarum CRNB-22 (KCTC11931 BP) strain having ginseng extract efficacy and saponin conversion method using the same. Korean Registered Patent No. 1345226, Novel 213 of the Fanny Bacillus family, a composition for preventing or treating atopic dermatitis containing fermented ginseng extract and fermented ginseng extract using the same, 2013. 12. 19. Registered. Korean Patent Laid-Open Publication No. 2014-0061915, a new microorganism Bacillus coagulans KM-1, and a method for producing fermented soybean meal and fish meal using the same, 2014. 05. 22. Published.

In - Kyu Han, Feed Engineering, Advanced Cultural History, 67 ~ 107, 1998. Akao T. et al., Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng, J. Pharm. Pharmacol., 50 (10), 1155-1160, 1998. Hasegawa H. et al., Main ginseng saponin metabolites formed by intestinal bacteria, Planta Med., 62 (5), 453-457, 1996. Shibata S. et al. Studies on the constituents of Japanese and Chinese crude drugs. XI. Panaxadiol, a sapogenin of ginseng roots, Chem. Pharm. Bull. 11,759-761,1963. Shibata S. et al., Studies on the saponins of Ginseng. Ⅱ. Structures of ginsenoside-Re, -Rf and -Rg2, Chem. Pharm. Bull. 22, 2407-2421, 1974. Shibata S. et al., Studies on the saponins of Ginseng. I. Structures of ginsenoside-Ro, -Rb1, -Rb2, -Rc and -Rd, Chem. Pharm. Bull. 22, 421-428, 1974. Stale R. et al., Nutrient digestibility in Atlantic salmon and broiler chichens related to viscosity and non-starch polysaccharide content in different soyabean products, Aniaml Feed Science and Technology, 97 (4), 331-345, 1999.

It is an object of the present invention to provide a novel Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) and fermented ginseng using the same.

It is another object of the present invention to provide a probiotic prophylactic composition using the Bacillus coagulans NRR1207 strain.

The present invention relates to a novel Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P).

The present invention also relates to a method for producing fermented ginseng using Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, microorganism accession number KACC92114P) and fermented ginseng prepared thereby.

The present invention also relates to a probiotic probiotic composition comprising a Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P).

Hereinafter, the present invention will be described in detail.

The optimal growth temperature of the strain of Bacillus coitalis NRR1207 is 30 ° C to 40 ° C, preferably 35 ° C, and the optimal development pH range of the strain is 6.0 to 7.0, preferably 6.5.

The above-mentioned Bacillus coagulans NRR1207 ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) is an alkaline phosphatase, an esterase, an esterase lipase, a lipase, Leucinearylamidase, valinearylamidase, acid phosphatase, naphtol-AS-BO-phosphohydrolase,? -Galactose Glucuronidase,? -Glucosidase,? -Glucuronidase,? -Glucosidase,? -Glucosidase (? -Glucosidase,? -Glucosidase, β-glucosidase, N-acetyl-β-glucosamidase and α-mannosidase enzymes.

The? -Glucosidase enzyme has an activity of converting ginsenosides and can convert ginsenosides having a low water absorption rate into ginsenosides having a high water absorption rate.

More specifically, the β-glucosidase enzyme possessed by the Bacillus coagulans NRR1207 strain of the present invention ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) has the ability to convert ginsenosides Rb1 and Rb2 into ginsenoside Rd And the conversion activity of ginsenoside Rb1 to ginsenoside Rd is particularly excellent.

The α-galactosidase also hydrolyzes the α-D-galactosidic bond and liberates D-galactose, which also acts on degradation of the indigestible polysaccharide.

The? -Galactosidase enzyme possessed by the Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) of the present invention is an oligosaccharide such as cellulose, hemicellulose, Pectin, starchyose, and raffinose, and more preferably starchyose and raffinose.

In addition, the Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) of the present invention has an enzyme activity to degrade a protein.

The present invention relates to a method for producing fermented ginseng using the above-mentioned Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, microorganism accession number KACC92114P), comprising the steps of i) cutting ginseng roots to 15% to 25%, preferably 20% Preparing a ginseng solution; ii) heating the ginseng solution at 65 ° C to 85 ° C for 5 minutes to 15 minutes, preferably at 75 ° C for 10 minutes; iii) Inoculating the heated ginseng solution with Bacillus coagulans NRR1207 strain; And iv) fermenting the ginseng solution inoculated with the strain at 20 ° C to 40 ° C for 7 days to 14 days, preferably at 30 ° C for 11 days; . ≪ / RTI >

The present invention also relates to fermented ginseng produced through the above-described production method.

The ginseng used in the preparation of the fermented ginseng is a perennial plant belonging to the genus Panax , and is a perennial plant belonging to the genus Panax ginseng ( Panax ginseng ), Panax quinquefolia , Panax notoginseng , Panax japonicus , ( Panaxa pseudoginseng ). And one species selected from Panax vietnamensis , Panax elegatior , Panax wangianus and Panax bipinratifidus , Panax angustifolium , Ginseng can be used, but is not limited thereto. These ginsengs may be used alone or in combination of two or more.

It is preferable that the ginseng is roots of ginseng which is 4 to 6 years old.

The present invention also relates to a probiotic probiotic composition comprising a Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P).

The probiotic agent refers to a product containing microorganisms beneficial to the living body, and is divided into two types for domestic use for fermentation, diarrhea, insufficient digestion, and domestic animals for enhancing productivity such as promotion of development of livestock and prevention of diarrhea. Probiotics probiotics for livestock are probiotics probiotics for livestock feed, which accelerate the degradation of indigestible polysaccharides contained in livestock feeds, thereby helping digestion and absorption of livestock into the intestines.

The present invention provides a novel Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) and fermented ginseng using the same. The Bacillus coagulans NRR1207 strain is excellent in converting ginsenosides of low-bioavailability ginseng into ginsenosides with good bioavailability.

Also provided is a probiotic prophylactic composition using the novel Bacillus coagulans NRR1207 strain of the present invention. The above-mentioned Bacillus coagulans NRR1207 is excellent in the function of decomposing the stubbyose and raffinose which are the indigestible components contained in the raw materials for feeds.

Therefore, it is expected that the novel Bacillus coagulans NRR1207 strain of the present invention can be used in the development of health functional foods and in the development of probiotics and protein-degrading livestock preparations for livestock.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows a 16s rDNA gene sequence (A) and a molecular phylogenetic classification (B, lower end, NRR1207) of Bacillus coagulans NRR1207 strain.
FIG. 2 is a graph showing the conversion of ginsenoside components of fermented ginseng reacted with Bacillus coagulans NRR1207 at 30 ° C. for 0 days (A), 7 days (B) and 14 days (C) Results are shown.
Fig. 3 shows the results of measurement of the number of viable cells of Bacillus coa mandarin NRR1207 according to fermentation time using solid phase fermentation of soybean meal.
Figure 5 shows HPLC standard graphs of fructose, glucose, melibiose, stachyose, sucrose and raffinose for carbohydrate analysis of soybean meal.
Fig. 6 shows the result of carbohydrate analysis of soybean meal after solid-phase fermentation of soybean meal using Bacillus coagulans NRR1207 strain. To determine the change of carbohydrate in soybean meal according to fermentation time, the samples were analyzed by HPLC using 0 day (A), 1 day (B), 3 days (C) and 7 day (D) samples.

Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, the intention is to provide an exhaustive, complete, and complete disclosure of the principles of the invention to those skilled in the art.

≪ Example 1: Isolation and identification of new microorganisms >

In order to select Bacillus species capable of β-glucosidase secretion while producing lactic acid-functioning lactic acid bacteria, the fermentation broth for the microbial isolate was cultured in lactic acid-selective medium (BCP, yellow) and S And cultured at 37 占 폚 and 30 占 폚 in a cool medium (esculine agar, confirmed as? -Glucosidase activity, changed to dark brown). After culturing, colonies showing activity were isolated and analyzed for 16S rDNA.

The DNA of the strain was extracted and analyzed for 16S rDNA. The strain DNA was extracted and PCR was performed using a 27F primer set (5'-AGAGTTTGATCACTGGCTCAG-3 ', 5'-GGTTACCTTGTTACGACTT-3) to amplify 16S rDNA (16S rRNA coding gene). The amplification conditions were pre-denaturation at 95 ° C for 3 minutes, followed by 30 cycles of denaturation at 94 ° C for 20 seconds, annealing at 56 ° C for 40 seconds, extension at 72 ° C for 40 seconds, and final extension at 72 ° C for 3 minutes Respectively. Amplified 16S rDNA was purified using a PCR kit (Product Purification Kit, Qiagen) and analyzed using genetic analyzer 377 (Perkin-Elmer).

16S rDNA sequence (see Fig. 1A) molecular phylogenetic analysis, Bacillus (Bacillus) in lance Bacillus core tangerine a strain belonging to the (genus) (Bacillus coagulans) strain showing the highest homology between the type strain and 99.9% based on (See FIG. 1B). Therefore, the strain was identified as a Bacillus subtilis strain and named as Bacillus coagulans NRR1207 ( Bacillus coagulans NRR1207) and deposited with the National Institute of Agricultural Science and Technology, National Institute of Agricultural Science and Technology, Information Center, December 15, 2015, Microorganism Accession No. KACC92114P.

≪ Example 2: Identification of enzyme activity of isolate &

An API ZYM kit (BioMerieux Inc., Mercy I 'Etoile, France) was used to confirm the enzyme activity of the Bacillus coitalis NRR1207 strain identified in Example 1 above.

The selected strains were suspended in a liquid medium (0.085% NaCl, Ref 20070, Bio Merieux, France), adjusted to standard turbidity concentration McFarland No 5.0-6.0 standard (Bio Merieux, France) and then immobilized on API ZYM 19 dehydrated chromo- And the cells were suspended at 37 占 폚 for 4 hours. Enzyme activity was measured by the color of the cultured API kit based on the standard enzyme activity chart divided into 20, 30, 40 ≤ nanomoles.

In the case of the enzyme activity of Bacillus coagulans NRR1207, the maximum enzyme activity was set at 5, and enzyme activity was measured according to the color.

enzyme activation Control group 0 Alkaline phosphatase (Alkaline phosphatase) 4 Esterase (C4) 4 Esterase lipase (C8) 4 Lipase (C14) One Leucinearylamidase < RTI ID = 0.0 > 3 Valinearylamidase < / RTI > One Cystinearylamidase < RTI ID = 0.0 > 0 Trypsin 0 α-chymotrypsin (α-chymotrypsin) 0 Acid phosphatase 5 Naphthol-AS-BO-phosphohydrolase
(Naphtol-AS-BO-phosphohydrolase) 5 α-galactosidase (α-galactosidase) 5 β-galactosidase (β-galactosidase) 5 β-glucuronidase (β-glucuronidase) 2 α-glucosidase (α-glucosidase) 5 β-glucosidase (β-glucosidase) 2 N-acetyl-β-glucosamidase (N-acetyl-β-glucosamidase) One α-mannosidase (α-mannosidase) One alpha-fucosidase < / RTI > 0

As shown in Table 1, in the case of the novel strain of Bacillus coagulans NRR1207 of the present invention, the activity of β-glucosidase which can convert ginsenoside, ginsenoside, is 2 And α-galactosidase activity, which is capable of decomposing ovarian stachyose and raffinose among cereal components, was 5, indicating that the enzyme activity was the maximum.

<Example 3> Preparation of fermented ginseng using Bacillus coagulans NRR1207 strain and confirmation of conversion effect of ginsenoside>

The ginseng roots were cut to prepare a 20% ginseng roots solution, and the mixture was heated at 75 ° C for 10 minutes. Bacillus coagulans NRR1207 of the present invention was inoculated thereto and cultured at 30 ° C for 7 days to 14 days. As a control, a sample not inoculated with Bacillus coagulans NRR1207 was used. After culturing, the culture was centrifuged at 6,000 × g for 3 minutes and the supernatant was taken and lyophilized.

HPLC (LC-6AD, Shimadzu Co., Japan) analysis was performed to confirm conversion of ginsenoside from the lyophilized supernatant, and the results are shown in Fig. An ACE 5-C ₁₈ column (250 x 4.6 mm) was used as the column, and conditions for analyzing the components of saponin are shown in Table 2 below.

Component analysis conditions of saponin column ACE 5-C ₁₈ (250 x 4.6 mm) flux
(Flow rate) 1.0 ml / min Detector
(Detector) UV detector, 205nm Solvent A; H ₂ O, B; CH ₃ CN
(35% B), 85- 105 minutes (50% B), 105-135 minutes (65% B), 135-145 minutes (85% B) 145-155 minutes (100% B), 155-160 minutes (100% B), 160-163 minutes (20% B), 163-165 minutes (20% B) Temperature 40 ℃

As shown in FIG. 2, the conversion of ginsenoside by ginseng roots fermentation decreased ginsenoside Rb1 in the sample on fermentation 7 days (FIG. 2B) and 14 days (FIG. 2C) Was significantly increased. This suggests that the enzyme secreted by Bacillus coagulans NRR1207 during fermentation resulted in the conversion of ginsenosides.

<Example 4> Determination of degradation effect of the indigestible component using Bacillus coagulans NRR1207 strain>

Example 4-1. Identification of Fermentation Time Conditions of Bacillus coa mandarin NRR1207 Using Solid State Fermentation of Soybean Meal

The fermentation time was checked by measuring the number of viable cells according to the solid-phase fermentation time of the Bacillus coagulans NRR1207 strain.

60 g of water was added to 40 g of soybean meal containing 10% water and Bacillus coagulans NRR1207 strain was inoculated as a starter to 5% of the weight of the soybean meal and water mixture. The mixture was incubated at 0, 4, 8, 12 , 16, 24, 48 and 72 hours, and the bacterial counts were diluted in decimal system and measured using BCP agar. The results of measurement of viable cell counts according to fermentation time are shown in Fig.

As can be seen from FIG. 3, when fermentation was performed for 0 to 16 hours, the viable cell count of Bacillus coagulans NRR1207 rapidly increased, and the viable cell number reached 9.45 × 10 ⁸ CFU / ml at 16 hours after fermentation, And it was confirmed that the viable cell count became 1.65 x 10 ⁸ CFU / ml at 72 hours after fermentation.

Example 4-2. Identification of degradation effects of indigestible components of Bacillus coagulans NRR1207 by solid phase fermentation of soybean meal

60 g of water was added to 40 g of soybean meal containing 10% of water, and Bacillus coagulans NRR1207 strain was inoculated to 5% of the weight of the soybean meal and water mixture and sealed with a plastic bag. The sealed soybean meal was incubated in a 35 ℃ incubator for 7 days and the carbohydrate of the soybean meal was separated and analyzed by HPLC. At this time, a standard graph was obtained using fructose, glucose, melibiose, stachyose, sucrose, and raffinose, and the results are shown in FIG. 4 .

As shown in Fig. 4, it can be seen that fructose is separated at 13.703 min, glucose at 12.673 min, melibiose at 10.843 min, stachyose at 9.333 min, sucrose at 10.9 min and raffinose at 9.947 min there was.

 5 shows changes in carbohydrate before and after fermentation of the soybean meal. As shown in FIG. 5, starch and raffinose were not separated in the case of the 0 day sample of soybean meal fermentation (FIG. 5A) but mixed at one peak at the same time. This is a result that can be obtained because the difference in separation time between stachyose and raffinose is very small as shown in the standard graph (Fig. 4). After 1 day of fermentation (Fig. 5B), stachyzes and raffinos were separated and their peaks were reduced in size. On the third day of fermentation (Fig. 5C), stachyose peaks disappeared and raffinose peaks It was found to be significantly smaller. On the 7th day of fermentation (Fig. 5D), it was confirmed that both stachyose and raffinose peaks were disappeared. These results indicate that starch and raffinose, which are the indigestible components of soybean meal, are completely degraded by Bacillus coagulans NRR1207 strain.

<Example 5> Culture of Bacillus coagulans NRR1207 strain>

Bacillus coagulans NRR1207 strain was inoculated to 1 liter of MRS medium (pH 6.5), which is a lactic acid bacterium culture medium, at 3% of the medium volume, and then cultured at 35 DEG C for 48 hours with stirring to obtain a strain.

National Academy of Agricultural Sciences KACC92114P 20151215

<110> The Industry & Academic Cooperation in Chungnam National University          CHUNG MI BIO CO., LTD. <120> Novel Bacillus coagulans NRR1207, fermented ginseng using the          same and probiotic composition containing the same <130> 15-0096 <160> 1 <170> KoPatentin 3.0 <210> 1 <211> 1447 <212> DNA <213> Bacillus coagulans <400> 1 tctgtcacct tcggcggctg gctccgtaag gttacctcac cgacttcggg tgttacaaac 60 tctcgtggtg tgacgggcgg tgtgtacaag gcccgggaac gtattcaccg cggcatgctg 120 atccgcgatt actagcgatt ccggcttcat gcaggcgggt tgcagcctgc aatccgaact 180 gggaatggtt ttctgggatt ggcttaacct cgcggtctcg cagccctttg taccatccat 240 tgtagcacgt gtgtagccca ggtcataagg ggcatgatga tttgacgtca tccccacctt 300 cctccggttt gtcaccggca gtcaccttag agtgcccaac tgaatgctgg caactaaggt 360 caagggttgc gctcgttgcg ggacttaacc caacatctca cgacacgagc tgacgacaac 420 catgcaccac ctgtcactct gtcccccgaa ggggaaggcc ctgtctccag ggaggtcaga 480 ggatgtcaag acctggtaag gttcttcgcg ttgcttcgaa ttaaaccaca tgctccaccg 540 cttgtgcggg cccccgtcaa ttcctttgag tttcagcctt gcggccgtac tccccaggcg 600 gagtgcttaa tgcgttagct gcagcactaa agggcggaaa ccctctaaca cttagcactc 660 atcgtttacg gcgtggacta ccagggtatc taatcctgtt tgctccccac gctttcgcgc 720 ctcagcgtca gttacagacc agagagccgc cttcgccact ggtgttcctc cacatctcta 780 cgcatttcac cgctacacgt ggaattccac tctcctcttc tgcactcaag cctcccagtt 840 tccaatgacc gcttgcggtt gagccgcaag atttcacatc agacttaaga agccgcctgc 900 gcgcgcttta cgcccaataa ttcccggaca acgcttgcca cctacgtatt accgcggctg 960 ctggcacgta gttagccgtg gctttctggc cgggtaccgt caaggcgccg ccctgttcga 1020 acggcacttg ttcttccccg gcaacagagt tttacgaccc gaaggccttc ttcactcacg 1080 cggcgttgct ccgtcagact ttcgtccatt gcggaagatt ccctactgct gcctcccgta 1140 ggagtttggg ccgtgtctca gtcccaatgt ggccgatcac cctctcaggt cggctacgca 1200 tcgttgcctt ggtgagccgt taccccacca actagctaat gcgccgcggg cccatctgta 1260 agtgacagca aaagccgtct ttcctttttc ctccatgcgg aggaaaaaac tatccggtat 1320 tagccccggt ttcccggcgt tatcccgatc ttacaggcag gttgcccacg tgttactcac 1380 ccgtccgccg ctaacctttt aaaagcaagc ttttaaaagg tccgcacgac tgcatgtata 1440 gcncgcc 1447

Claims (11)

A novel strain of Bacillus coagulans NRR1207 ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P). The method according to claim 1,
The above-mentioned Bacillus coagulans NRR1207 ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) is an alkaline phosphatase, an esterase, an esterase lipase, a lipase, Leucinearylamidase, valinearylamidase, acid phosphatase, naphtol-AS-BO-phosphohydrolase,? -Galactose Glucuronidase,? -Glucosidase,? -Glucuronidase,? -Glucosidase,? -Glucosidase (? -Glucosidase,? -Glucosidase, characterized in that it has at least one enzyme activity from the group consisting of N-acetyl-β-glucosidase, N-acetyl-β-glucosamidase and α-mannosidase Bacillus coagulans NRR1207 strain. 3. The method of claim 2,
The Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) has the activity of? -Glucosidase and? -Galactosidase enzymes. The method of claim 3,
The β-glucosidase enzyme activity converts Bacillus coagulans NRR1207 ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P), which converts ginsenoside Rb1 to Rd. The method of claim 3,
Wherein said? -Galactosidase enzyme activity decomposes an indigestible component comprising cellulose, hemicellulose, pectin, stachyose and raffinose. Coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P). 6. The method of claim 5,
The Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P) is characterized in that the? -Galactosidase enzyme activity decomposes stachyose and raffinose. A method for producing fermented ginseng using Bacillus coaculans NRR1207 strain ( Bacillus coagulans NRR1207, microorganism accession number KACC92114P)
i) cutting ginseng roots to prepare 15% to 25% ginseng solution;
ii) heating the ginseng solution at 65 占 폚 to 85 占 폚 for 5 minutes to 15 minutes;
iii) Inoculating the heated ginseng solution with Bacillus coagulans NRR1207 strain; And
iv) fermenting the ginseng solution inoculated with the strain at 20 ° C to 40 ° C for 7 days to 14 days;
&Lt; / RTI &gt; The fermented ginseng according to claim 7, which is produced by using the fermented ginseng. A probiotic probiotic agent comprising Bacillus coagulans NRR1207 strain ( Bacillus coagulans NRR1207, Microorganism Accession No. KACC92114P). 10. The method of claim 9,
Probiotics Probiotics are probiotics probiotics for human use and livestock. 11. The method of claim 10,
Wherein the probiotics probiotics prophylactic agent for livestock is for livestock feed.

Images